Investors should scoop up shares of medical device provider AtriCure , according to JMP Securities, which expects the company to be a winner in one burgeoning medical device market. AtriCure develops, manufactures and sells devices that are used for the treatment of atrial fibrillation, or Afib; left atrial appendage management, or LAAM; and post-operative pain. The company's stock price has declined just about 19% so far this year, with almost all of that occurring this quarter. ATRC YTD mountain AtriCure stock. AtriCure's pain management division "adds an attractive layer of growth that should outpace ATRC's legacy product portfolios," Stauder said.

---

Persons: Daniel Stauder, Stauder, bode, AtriCure, — CNBC's Michael Bloom Organizations: JMP Securities